Tg Therapeutics (TGTX) Income from Non-Controlling Interests (2011 - 2012)
Tg Therapeutics (TGTX) recorded quarterly Income from Non-Controlling Interests of -$247962.0 in Q3 2012, up 63.51% quarter-over-quarter from -$679506.0 in Q2 2012, and down 16321.32% on a YoY basis from N/an in Q4 2011.
Tg Therapeutics (TGTX) Income from Non-Controlling Interests (2011 - 2012) Analysis & Trends
Tg Therapeutics' Income from Non-Controlling Interests history runs 2 years deep, the most recent figure standing at -$247962.0 for Q3 2012.
- In Q3 2012, Income from Non-Controlling Interests fell 16321.32% year-over-year to -$247962.0; the TTM figure through Sep 2013 stood at -$247962.0 (up 96.93% YoY), while the FY2012 annual figure was -$8.1 million, down 22430.3% from the prior year.
- Income from Non-Controlling Interests was -$247962.0 for Q3 2012 at Tg Therapeutics, up from -$679506.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$1510.0 in Q3 2011 to a low of -$7.1 million in Q1 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Tg Therapeutics | 7.71 Bn | 7.06 Bn | 171.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | -247,962.00 |
| Jun 30, 2012 | -679,506.00 |
| Mar 31, 2012 | -7.14 Mn |
| Dec 31, 2011 | -19,592.00 |
| Sep 30, 2011 | -1,510.00 |
| Jun 30, 2011 | -14,895.00 |